European Medicines Agency recommends granting a marketing authorisation for radium-223 chloride

The European Medicines Agency Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product radium-223 chloride (Xofigo), 1000 kBq/mL, solution for injection, intended for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Read more here.